CGTLimited DatastaleOttawa Heart Institute Research…Phase 3
Point-of-care genetic screening with subsequent prasugrel administration to CYP2C19*2 carriers (Point-of-care genetic screening with subsequent prasugrel administration to CYP2C19*2 carriers)
Stable Coronary Artery Disease; Acute Coronary Syndrome · Stable Coronary Artery Disease
#StableCoronaryArteryDisease#CGT#Phase3#cell-gene-therapy#CAR-T+3
Trials 1Status Active